Kane Biotech Restarts Commercial Activities and Strengthens North American Management

The company is expanding distribution of its revyve Antimicrobial Wound Gel products in the U.S. and Canada.

Published on Feb. 12, 2026

Got story updates? Submit your updates here. ›

Kane Biotech Inc. has announced the resumption of commercial activities in both the United States and Canada for its revyve Antimicrobial Wound Gel product line, alongside the appointment of two seasoned industry leaders to drive business development across North America. The company has signed non-exclusive distribution/sales agreements in the U.S. and resumed commercial activity in Canada, marking a meaningful restart of Kane's commercial engine.

Why it matters

Kane Biotech's revyve products are designed to disrupt biofilms and transform wound healing outcomes. Biofilms are a major contributor to antibiotic resistance in wounds, leading to serious clinical issues and high costs. The company's restart of commercial activities and new leadership hires aim to drive adoption of its innovative wound care solutions across North America.

The details

In the U.S., Kane has signed non-exclusive distribution/sales agreements with Medstream Healthcare Solutions, LLC and Patient Care Medical, with initial shipments expected soon. In Canada, the company has resumed commercial activity by converting its distribution agreement with Best Buy Medical Canada to a non-exclusive arrangement, along with targeted sales and sampling initiatives. To support this next phase of growth, Kane has appointed Sherida (Kay) Watkins Weaver as Vice President of Business Development for the U.S. and Patti Burke-Martin as Vice President of Business Development for Canada.

  • Kane Biotech announced the resumption of commercial activities on February 12, 2026.

The players

Kane Biotech Inc.

A company commercializing and developing novel wound care treatments that disrupt biofilms and transform healing outcomes.

Dr. Robert Huizinga

The Interim CEO of Kane Biotech.

Sherida (Kay) Watkins Weaver

The new Vice President of Business Development for the United States at Kane Biotech, bringing over 20 years of experience in wound care commercialization.

Patti Burke-Martin

The new Vice President of Business Development for Canada at Kane Biotech, a national wound care leader with a proven track record in building high-performing teams and driving adoption of advanced wound care technologies across Canada.

Medstream Healthcare Solutions, LLC

A distribution/sales partner for Kane Biotech's revyve products in the U.S.

Patient Care Medical

A distribution/sales partner for Kane Biotech's revyve products in the U.S.

Best Buy Medical Canada

Kane Biotech's distribution partner in Canada, with whom the company has converted to a non-exclusive arrangement.

Got photos? Submit your photos here. ›

What they’re saying

“We are executing on our commitment to reset Kane Biotech using a disciplined market approach. We will continue to generate scientific credibility, clinical validation and with that, the commercial infrastructure.”

— Dr. Robert Huizinga, Interim CEO of Kane Biotech (businessinsider.com)

“Kay and Patti bring deep expertise and trusted relationships in their respective markets. Their leadership will be instrumental as we expand our distribution network and support the growing adoption of revyve.”

— Dr. Robert Huizinga, Interim CEO of Kane Biotech (businessinsider.com)

The takeaway

Kane Biotech's restart of commercial activities and new leadership hires demonstrate the company's commitment to driving adoption of its innovative revyve wound care products across North America, with the goal of disrupting biofilms, transforming healing outcomes, and addressing the growing challenge of antibiotic resistance in wound care.